Apellis Pharmaceuticals (STU:1JK) Current Accrued Expense : €96.3 Mil (As of Sep. 2024)

View and export this data going back to 2023. Start your Free Trial

What is Apellis Pharmaceuticals Current Accrued Expense?

Apellis Pharmaceuticals's Current Accrued Expense for the quarter that ended in Sep. 2024 was €96.3 Mil.

Apellis Pharmaceuticals's quarterly Current Accrued Expense declined from Mar. 2024 (€93.3 Mil) to Jun. 2024 (€93.0 Mil) but then increased from Jun. 2024 (€93.0 Mil) to Sep. 2024 (€96.3 Mil).

Apellis Pharmaceuticals's annual Current Accrued Expense declined from Dec. 2021 (€91.4 Mil) to Dec. 2022 (€89.8 Mil) but then increased from Dec. 2022 (€89.8 Mil) to Dec. 2023 (€117.2 Mil).

Apellis Pharmaceuticals Current Accrued Expense Historical Data

The historical data trend for Apellis Pharmaceuticals's Current Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Apellis Pharmaceuticals Current Accrued Expense Chart

Apellis Pharmaceuticals Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Current Accrued Expense

Get a 7-Day Free Trial

49.31

92.01

91.37

89.81

117.20

Apellis Pharmaceuticals Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Current Accrued Expense	Get a 7-Day Free Trial															109.71	117.20	93.29	92.97	96.35

Apellis Pharmaceuticals Current Accrued Expense Calculation

Current Accrued Expense is the expense incurred during the accounting period, but not required to be paid until a later date. It includes compensation, interest, pensions and all other miscellaneous accruals reported by the company.

Apellis Pharmaceuticals Current Accrued Expense Related Terms

Thank you for viewing the detailed overview of Apellis Pharmaceuticals's Current Accrued Expense provided by GuruFocus.com. Please click on the following links to see related term pages.

Apellis Pharmaceuticals Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Apellis Pharmaceuticals Inc (STU:1JK) » Definitions » Current Accrued Expense

Comparable Companies

Traded in Other Exchanges

APLS:USA

Address

100 Fifth Avenue, Waltham, MA, USA, 02451

Website

https://www.apellis.com

Apellis Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutic compounds to treat diseases with high unmet needs through the inhibition of the complement system, which is an integral component of the immune system, at the level of C3, the central protein in the complement cascade.

Apellis Pharmaceuticals Headlines

No Headlines